Florbenazine | 937245-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: Florbenazine
• 英文别名: (2R,3R,11bR)-9-(3-fluoropropoxy)-10-methoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
• CAS: 937245-42-6
• 化学式: C₂₁H₃₂FNO₃
• 分子量: 365.5
• InChiKey: GNKGXQHHUUEYQV-BHIYHBOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP2604290A2

  公开（公告）日：2013-06-19

  This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. This invention also relates to compounds, and methods of monitoring progression of a disease related to vesicular monoamine transporters.

  本发明涉及一种对囊泡单胺转运体成像的方法和标记化合物及其药物组合物，以及用于对囊泡单胺转运体成像的标记化合物的制造方法。本发明还涉及化合物以及监测与囊泡单胺转运体有关的疾病进展的方法。
• Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
  申请人：Five Eleven Pharma Inc.

  公开号：US10912849B2

  公开（公告）日：2021-02-09

  The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

  本发明涉及符合式 I-A、式 II-A、式 II-D 和式 III-A 的氚代化合物。这些化合物可用作 PET 成像剂，用于评估帕金森病、阿尔茨海默病，以及确定治疗抑郁症的特异性血清素再摄取抑制剂 (SSRIi) 的活性。本发明还涉及药物组合物，其包含药物可接受载体和式 I-A、式 II-A、式 II-D 或式 III-A 的化合物或其药物可接受盐。
• METHODS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP2534136B1

  公开（公告）日：2017-09-06
• NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION
  申请人：Five Eleven Pharma Inc.

  公开号：US20200230263A1

  公开（公告）日：2020-07-23

  The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
• US8562949B2
  申请人：——

  公开号：US8562949B2

  公开（公告）日：2013-10-22